Immunohistochemistry News and Research

RSS

Immunohistochemistry (IHC) is an imaging technique to visualize antigens in cells. Labeled antibodies bind to target antigens in the cell to image the distribution and localization of specific proteins of interest

IL-22 plays critical role in normal lung repair following influenza infection

Once the initial episode of influenza has passed, the chronic effects tend to be overlooked. The results of a new study indicate that the cytokine interleukin-22 (IL-22) plays a critical role in normal lung repair following influenza infection. This study is published in the April 2013 issue of the American Journal of Pathology.

11 Mar 2013

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody program to enter the clinic in just three years from initiation of discovery.

7 Jan 2013

DNA adducts linked to oral cancer in smokers

Having a high susceptibility to certain types of DNA damage caused by tobacco smoking could significantly increase the risk for oral cancer, show results of a Taiwanese study.

28 Dec 2012

Immunohistochemistry reliable in identifying ALK rearrangement: Study

Favorable results have led to crizotinib gaining approval for the treatment of advanced stage ALK-positive non-small cell lung cancer (NSCLC) in Japan, the United States, Canada, and several other countries in Europe and Asia.

17 Dec 2012

New diagnostic assay for screening ALK fusions in non-small cell lung carcinoma

Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients are highly responsive to ALK-specific kinase inhibitors such as crizotinib.

From NanoString Technologies 13 Dec 2012

Studies explore F-18-FLT PET utility in providing prognostic information for patients with gliomas

In the management of gliomas-or tumors that originate in the brain-precise assessment of tumor grade and the proliferative activity of cells plays a major role in determining the most appropriate treatment and predicting overall survival.

4 Dec 2012

Transcription factor expression aids stage I lung cancer prognosis

Expression of thyroid transcription factor-1 is an independent predictor for recurrence of stage I lung adenocarcinoma and allows intermediate-grade tumors to be split into two prognostic subsets, scientists have found.

16 Nov 2012

UK scientists make breakthrough in new method of brain tumour diagnosis

UK scientists have made a breakthrough in a new method of brain tumour diagnosis, offering hope to tens of thousands of people.

20 Sep 2012

Predicting breast cancer drug response by 20/20 GeneSystems’ PredicTOR test

20/20 GeneSystems, Inc. will present results this week at the Breast Cancer Symposium 2012 (San Francisco) of a 45 patient study showing the usefulness of its PredicTOR test in predicting response of breast tumors to the drug Herceptin.

13 Sep 2012

FISH assay identifies only few lung cancer patients who could benefit from crizotinib

Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails - such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.

29 Aug 2012

S45F mutation may offer identifiable risk factor in recurrent pediatric aggressive fibromatosis

In the case of aggressive fibromatosis, the good news is that it is a slow-growing benign tumor. The bad news is that this abdominal tumor often recurs after surgical removal. This is particularly true among children. While headway has been made in isolating causes of this recurrence in adults, it is less clear in children.

23 Aug 2012

Folate, excision biomarkers not predictive for small-cell lung cancer response

Biomarkers associated with the folate metabolism and excision repair pathways are not sufficiently prognostic to aid chemotherapy decisions for patients with extensive-stage disease small-cell lung cancer, results of a phase III trial show.

8 Aug 2012

NeoGenomics second quarter 2012 revenue increases 49% to $15.6 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the second quarter 2012.

19 Jul 2012

bioTheranostics’ CancerTYPE ID molecular test improves overall survival for patients with CUP

bioTheranostics, developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced study results showing that tumor profiling with its CancerTYPE ID molecular test helped guide site-specific chemotherapy and improve overall survival for patients with carcinoma of unknown primary site.

6 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

GE Healthcare today announced results from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial at the 2012 Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC).

4 Jun 2012

Studies support diagnostic utility of molecular classification in difficult-to-diagnose metastatic cancer

bioTheranostics, Inc., developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced findings from two studies showing high diagnostic accuracy for CancerTYPE ID in determining the primary tumor site in high-grade, metastatic tumors. Results were reported at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

2 Jun 2012

Kindstar, Insight Genetics collaborate to improve cancer care in China

Molecular diagnostics company Insight Genetics and Kindstar Globalgene Technology, Inc., China's leading diagnostics company, today announced that the companies are partnering to enhance cancer care in the People's Republic of China and surrounding regions.

1 Jun 2012